This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Karmanos Genitourinary Team Leader Contributes To Article On Prostate Cancer In New England Journal Of Medicine

All patients on the trial had a form of prostate cancer that is referred to as 'castrate-resistant,' a stage of prostate cancer when the traditional testosterone suppression treatment is no longer effective against the cancer.

Dr. Vaishampayan noted that all men who are diagnosed with metastatic, hormone-sensitive prostate cancer on androgen deprivation become castrate-resistant within a median of 18-24 months after their initial diagnosis. The study established parameters for assessing the risk factors of early onset castrate-resistant disease, she said.

"The information that complete androgen deprivation and intermittent androgen deprivation have different survival outcomes should be an important factor during patient and physician discussions and decisions regarding the risks and benefits of androgen-deprivation therapy," Dr. Vaishampayan said. "This national trial addressed an important question and involved tremendous effort, patients and collaboration.

"I am proud to represent a fine institution like Karmanos Cancer Center, which is committed to clinical research for improving outcomes in patients with prostate cancer," she added. "I am indebted to the patients who enrolled in this trial and, in turn, helped countless others afflicted with the disease. Karmanos' clinical trials staff also was very dedicated to the cause and worked tirelessly to help us achieve our goals."       

About the Barbara Ann Karmanos Cancer Institute Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $265 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to .

SOURCE Karmanos Cancer Institute

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs